State-of-the-Art Technology for Insulin Therapy in Type 1 Diabetes: Engineering and Cell-based Approaches

Sponsored by: Covance

Focused on:

    Date: 13 May


    Time: 4PM London/11AM New York

    The management landscape for Type 1 diabetes (T1DM) has changed drastically since the inception of insulin replacement therapies. Today, automated insulin delivery with closed-loop technology and advances in regenerative medicine can improve glycemic control, reduce patient disease burden and decrease insulin use.

    While these advances are driven by a clear medical need, innovations with cell-based replacement therapies and various technologies often add complexities to clinical trial design and implementation.

    This educational webinar will provide an overview of current T1DM devices and capabilities such as automated closed-loop control and cell-based replacement therapies, encapsulation strategies and cellular engineering. The presentation will also highlight current innovations, address existing gaps and discuss the inherent challenges of meeting requirements and timelines in the development of these unique devices and therapies.

    Join this informative presentation to hear from thought leaders in the field as they share their applicable research experiences and explore the current state of technologies and regenerative medicine.

    Presented by

    Barry Goldstein, MD, PhD, FACE,

    Vice President & Therapeutic Area Head, CVMER, Covance

    Dr. Barry J. Goldstein is a board-certified endocrinologist who is an internationally-recognized authority on diabetes mellitus. Dr. Goldstein has over 25 years of broad experience in clinical and basic R&D in Academia and Industry, serving as the PI or Co-PI on nearly 100 clinical trials. He is an elected member of the ASCI and AAP, a past associate editor of the two major journals in his specialty, DIABETES and the Journal of Clinical Endocrinology and Metabolism, and has served on many grant panels for NIH, ADA and JDRF as well as industry scientific advisory panels.

    Dr. Goldstein received his combined MD/PhD degrees from the University of Rochester School of Medicine and Dentistry. His postdoctoral research and clinical fellowships were at the Joslin Diabetes Center and Brigham and Women's Hospital, both of Harvard Medical School, where he also served on the medical faculty for several years.

    *CVMER - Cardiovascular, Metabolic, Endocrinology & Renal

    Manasi Jaiman, MD, MPH,

    Senior Medical Director, CVMER, Covance

    Dr. Manasi Jaiman has extensive clinical and academic experience in pediatric T1DMand also provides medical and scientific expertise for clinical trials and protocols in diabetes and diabetes devices. Before joining Covance, Dr. Jaiman was involved in a variety of clinical research activities including a role as a lead clinician for a major T1DM program developing a dual-chambered “bionic pancreas” programmed to deliver insulin and glucagon in response to real-time glucose sensor monitoring data in ambulatory patients.

    Dr. Jaiman received an MPH in Health Systems Management from Tulane University before obtaining her MD from the Medical University of South Carolina. Dr. Jaiman completed her pediatric residency at Dartmouth-Hitchcock Medical Center and her Pediatric Endocrinology Fellowship at Massachusetts General Hospital (MGH) in Boston, Massachusetts where she continues to remain on faculty as assistant professor in Pediatrics and instructor at Harvard Medical School.

    Howard Foyt, MD, PhD, FACP,

    Vice President, Clinical Development and Chief Medical Officer, ViaCyte

    Dr. Foyt has over 22 years of clinical development experience in pharmaceutical and biotechnology environments. His background as an endocrinologist and his multiple NDA and IND applications position him as ViaCyte’s strategic leader for clinical and regulatory operations. Prior to ViaCyte, Dr. Foyt served as senior vice president and chief medical officer at Cebix, Inc., a company focused on treatments for complications of T1DM. Before Cebix, he was vice president, Clinical Development at Metabasis Therapeutics, Inc. Dr. Foyt's pharmaceutical experience includes senior positions at Pfizer Global Research & Development and Parke-Davis Pharmaceutical Research. As a clinician, Dr. Foyt was assistant professor and Medical Director of the University Diabetes Center at the University of Texas Medical Branch.

    He earned his medical degree from Baylor College of Medicine where he also earned a PhD in Cell Biology. Dr. Foyt completed his residency in internal medicine at Baylor and an endocrinology fellowship at the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.

    Key Learning Objectives

    • Gain insights on technological advances in T1DM control
    • Learn about challenges and gaps with current devices and capabilities
    • Get an overview of regenerative medicine and cell-based replacement therapies
    • Hear about managing timelines for developing therapies and unique devices


    • Chief Medical Officer Chief Executive officer Senior Medical Director Medical Director
    • Clinical Development Director
    • Research and Development Director
    • Operational Director
    • Senior Operational Director
    • Clinical Director
    • Senior Clinical Director
    • Research Director